A well-characterized research material can still produce an untraceable experiment if the laboratory loses its connection to the lot used. Inventory records should make that connection simple to reconstruct, especially when several similar materials are present.

FDA's records-and-reports guidance concerns the documentation needed to demonstrate drug-quality compliance. Used as an explanatory benchmark, it reinforces a general research principle: a conclusion is easier to evaluate when the underlying records remain available and understandable. FDA CGMP records and reports questions

Keep the identifiers stable

The supplier name, material identity, lot number, receipt date and relevant analytical record should be linked to the laboratory's internal identifier. If the material is divided or relabeled under an approved laboratory process, preserve the relationship to the original container. An internal nickname should not replace the scientific identity.

Experimental records should identify which lot was used rather than only the generic compound name. That detail can become decisive when a later investigation finds a difference between batches. It also helps a team reproduce work without guessing which purchase supported an earlier result.

Record status separately from location

Knowing where a container sits is not the same as knowing whether it has been reviewed for the intended experiment. A laboratory can distinguish received, under review, accepted for a specified purpose and excluded material using its established procedures. The record should explain who made the decision and why.

This AXON article proposes a documentation principle, not changes to any organization's inventory system. A qualified owner should approve actual workflow changes. Traceability can support research quality, but it does not make a reagent an approved medicine or establish permission for human use.